Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study (Front. Immunol., (2021), 12, (709861), 10.3389/fimmu.2021.709861)

Corrigendum: Nasal Administration of Anti-CD3 Monoclonal Antibody (Foralumab) Reduces Lung Inflammation and Blood Inflammatory Biomarkers in Mild to Moderate COVID-19 Patients: A Pilot Study (Front. Immunol., (2021), 12, (709861), 10.3389/fimmu.2021.709861)

Clare M. Baecher-Allan was not included as an author in the published article. The corrected Author Contributions Statement appears below. The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been upda...

Full description

Bibliographic Details
Main Authors: Baecher-Allan, C.M (Author), Chen, K. (Author), Cortina, A.S (Author), Da Mata, R.G (Author), De Paula, G.S (Author), Dedivitis, R.A (Author), Healey, B.C (Author), Izzy, S. (Author), Jacob, J. (Author), Keppeke, G.D (Author), Matos, K.T.F (Author), Moreira, T.G (Author), Palejwala, V. (Author), Pansera, F.C (Author), Rezende, R.M (Author), Santana, T.M.M (Author), Shailubhai, K. (Author), Spinola, M.G (Author), Weiner, H.L (Author)
Format: Article
Language:English
Published: Frontiers Media S.A. 2022
Subjects:
anti-CD3
COVID-19
erratum
foralumab
immune responses
SARS-CoV-2
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items